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Introduction
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology that affects the skin and a variety of internal organs. In early stages, inflammatory infiltrates are a histopathological hallmark of SSc (1) . The inflammatory infiltrates are dominated by monocytes and activated T cells. Later stages of the disease are characterized by an excessive accumulation of extracellular matrix components. The resulting fibrosis frequently leads to dysfunction of the affected organs, which is a major cause of death in SSc patients. The overproduction of extracellular matrix components in SSc patients is mediated by activated fibroblasts. The mechanisms leading to the activation of fibroblasts in SSc particular how leukocytes regulate this process are poorly understood so far (1) . The observation that activated fibroblasts that release excessive amounts of collagen, are mainly localized adjacent to inflammatory infiltrates support concepts that leukocytes constitute to initiation of fibrosis in early stages of SSc (2) .
In the early 1990s, two different receptors for the marijuana component Δ 9 -tetrahydrocannabinol have been identified and were named CB1 and CB2 (3, 4) . Both receptors are heterotrimeric GTP binding protein coupled receptors. CB1 is primarily expressed in the central nervous system, whereas CB2 is predominantly expressed in peripheral tissues. The ligands for CB1 and CB2, the so-called cannabinoids, can be subdivided into three different groups according to their origin. The family of cannabinoids includes plant derived cannabinoids, synthetic cannabinoids and endogenous cannabinoids (endocannabinoids) that are synthesized within the human body (5) . Besides their effects in the CNS, endocannabinoids regulate physiological and pathophysiological processes in nonneuronal tissues. Cannabinoids possess anti-tumor effects with inhibition of tumor cell proliferation and induction of cell cycle arrest in transformed cells. Endocannabinoids also orchestrate immune responses by regulating cytokine release, chemotaxis, proliferation and activation of leukocytes. Furthermore, cannabinoids play a central role for bone metabolism 4 and turn over as they control proliferation and activation of osteoblasts as well as differentiation of mononuclear precursor cells into osteoclasts (5, 6) . Endocannabinoids might also play a role in fibrotic diseases. Recent data demonstrated that cannabinoids regulate the activation of hepatic stellate cells, which contribute to the pathogenesis of liver fibrosis (7).
Stimulation of CB2 reduced the proliferation of hepatic stellate cells and reduced oxidative stress in preclinical models (7) . Expression of CB2 has also been found in the skin suggesting that CB2 signaling might play a role in dermal fibrosis (8-10).
The broad implication of the endocannabinoid system into different diseases resulted in considerable interest from pharmaceutical companies and stimulated the development of a number of synthetic small molecules that target the CB2 receptor. Several of these compounds are currently evaluated in clinical trials, e.g. selective CB2 agonists for immune modulation in multiple sclerosis (6) . First results from these trials indicate that a potent inhibition of the cannabinoid receptors can be achieved in humans and that the rate of severe adverse events of this class of drugs is low.
The aim of the present study was to investigate the role of the peripheral cannabinoid receptor CB2 in experimental dermal fibrosis. We demonstrate that inhibition of CB2 signaling either by gene silencing or by small molecule inhibitors increases the susceptibility to fibrosis. Moreover, activation of CB2 signaling reduced leukocyte infiltration into lesional skin and prevented the development of experimental fibrosis. Thus, stimulation of CB2 might be an interesting anti-fibrotic approach in early inflammatory stages of SSc.
Material and methods

Bleomycin-induced dermal fibrosis in CB2 deficient mice
Mice deficient for CB2 (CB2 -/-) have been described previously (11) . CB2 -/-mice were backcrossed onto a C57Bl/6 background for at least 6 generations. Matched wildtype C57Bl/6 mice expressing CB2 (CB2 +/+ ) from the same breedings were used as controls. Skin fibrosis was induced in 6-week-old mice by local injections of bleomycin for 4 weeks as described (12) . Briefly, 100 μl of bleomycin dissolved in 0.9% sodium chloride (NaCl) at a concentration of 0.5 mg/ml were administered every other day by subcutaneous injections in defined areas of 1 cm 
Effects of CB2 antagonists and agonists on experimental fibrosis
To confirm the increased susceptibility of CB2 irradiated, but did not receive bone marrow transplants. Two weeks after bone marrow transplantation and after confirmation of a complete reconstitution of the hematopoiesis by the transplanted cells, mice were challenged with bleomycin for 4 weeks as described above.
All groups of mice consisted of six animals each. 7 
Histological analysis
Lesional skin areas were excised, fixed in 4% formalin and embedded in paraffin. 5 µm sections were stained with hematoxylin and eosin. The dermal thickness was analyzed at 100-fold magnification by measuring the distance between the epidermal-dermal junction and the dermal-subcutaneous fat junction at three sites from lesional skin of each mouse (13) . 
Discussion
In the present study, we demonstrate that CB2 exerts anti-fibrotic effects in vivo. were also observed in the liver and pancreas (7, 14) . Based on these preclinical data, activation of CB2 by selective agonists might be a novel approach for the treatment of fibrosis. In SSc, this approach might be particular promising for patients in early inflammatory stages of the disease. Of note, CB2 agonists are currently evaluated in clinical trials for multiple sclerosis (5, 6) . In these clinical trials, CB2 agonists were well tolerated.
Major adverse events such as dizziness, drowsiness or headache were due to incomplete selectivity of these first compounds with co-activation of the CB1 receptor. Thus, our study could have direct clinical impact since CB2 agonists are well tolerated and already available for clinical trials in patients with fibrotic disorders such as SSc.
We show in vivo that CB2 mediates its anti-fibrotic effects by inhibiting the infiltration of leukocytes into lesional skin in preclinical models of SSc. bleomycin progresses during the first six weeks and that the fibrotic changes persist for at least 3 weeks after the last bleomycin injection (19 for the development of fibrosis in other organ systems such as the lung.
In summary, we demonstrate that CB2 exerts anti-fibrotic effects by limiting leukocyte infiltration and subsequent fibroblast activation in lesional skin. These data suggest that activation of CB2 might be a promising approach for therapy of early inflammatory stages of SSc. Since CB2 agonists are available and seem to be well tolerated, these findings might stimulate first clinical trials in patients with SSc and other fibrotic diseases. injected with NaCl. n = 6 for each group.
